Literature DB >> 12082566

Altered immunoreactivity of complexin protein in prefrontal cortex in severe mental illness.

K Sawada1, C E Young, A M Barr, K Longworth, S Takahashi, V Arango, J J Mann, A J Dwork, P Falkai, A G Phillips, W G Honer.   

Abstract

Recent imaging and postmortem studies suggest that impaired connectivity is involved in the pathophysiology of schizophrenia and major affective disorders. We investigated the presynaptic proteins complexin (Cx) I and Cx II in postmortem prefrontal cortex in schizophrenia (n = 13; six suicide, seven nonsuicide), major depression (n= 11, all suicide) and controls (n = 11) with an enzyme-linked immunoadsorbent assay (ELISA). Overall analysis indicated a significant difference between groups (F = 3.93, P = 0.007). Cx I (enriched in inhibitory terminals) was decreased 33% in schizophrenia (26% in schizophrenia/nonsuicide, 42% in schizophrenia/suicide) and 27% in major depression. Cx II (enriched in excitatory terminals) was not significantly different. Analysis of the ratio of Cx II/Cx I was carried out as an indication of the balance of excitatory to inhibitory terminals. A significant difference between groups (ANOVA, F = 6.42, P = 0.005) was observed. The mean value of Cx II/Cx I was significantly increased by 34% in schizophrenia (26% in schizophrenia/nonsuicide and 43% in schizophrenia/suicide) and by 32% in depression compared with control (Student-Newman-Keuls test, P = 0.05). Immunoreactivities of the two complexins were highly correlated in all groups. However, compared with controls and depression, samples from cases with schizophrenia appeared to have relatively less Cx I for similar amounts of Cx II. Immunocytochemical studies of rat frontal cortex after 3 weeks treatment with chlorpromazine, trifluoperazine or haloperidol revealed no differences in complexins, synaptophysin, SNAP-25, syntaxin or VAMP in comparison with animals treated with vehicle. Alterations of complexins may contribute to the molecular substrate for abnormalities of neural connectivity in severe mental disorders.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12082566     DOI: 10.1038/sj.mp.4000978

Source DB:  PubMed          Journal:  Mol Psychiatry        ISSN: 1359-4184            Impact factor:   15.992


  25 in total

Review 1.  The need for speed: an update on methamphetamine addiction.

Authors:  Alasdair M Barr; William J Panenka; G William MacEwan; Allen E Thornton; Donna J Lang; William G Honer; Tania Lecomte
Journal:  J Psychiatry Neurosci       Date:  2006-09       Impact factor: 6.186

2.  Synaptic protein deficits are associated with dementia irrespective of extreme old age.

Authors:  Michal Schnaider Beeri; Vahram Haroutunian; James Schmeidler; Mary Sano; Peter Fam; Aaron Kavanaugh; Alasdair M Barr; William G Honer; Pavel Katsel
Journal:  Neurobiol Aging       Date:  2011-12-27       Impact factor: 4.673

3.  RIM1alpha and interacting proteins involved in presynaptic plasticity mediate prepulse inhibition and additional behaviors linked to schizophrenia.

Authors:  Jacqueline Blundell; Pascal S Kaeser; Thomas C Südhof; Craig M Powell
Journal:  J Neurosci       Date:  2010-04-14       Impact factor: 6.167

4.  Lack of change in markers of presynaptic terminal abundance alongside subtle reductions in markers of presynaptic terminal plasticity in prefrontal cortex of schizophrenia patients.

Authors:  Samantha J Fung; Sinthuja Sivagnanasundaram; Cynthia Shannon Weickert
Journal:  Biol Psychiatry       Date:  2011-01-01       Impact factor: 13.382

5.  The reelin receptors VLDLR and ApoER2 regulate sensorimotor gating in mice.

Authors:  Alasdair M Barr; Kenneth N Fish; Athina Markou
Journal:  Neuropharmacology       Date:  2007-01-29       Impact factor: 5.250

6.  Associations of SNAP-25 polymorphisms with cognitive dysfunctions in Caucasian patients with schizophrenia during a brief trail of treatment with atypical antipsychotics.

Authors:  Ilja Spellmann; Norbert Müller; Richard Musil; Peter Zill; Anette Douhet; Sandra Dehning; Anja Cerovecki; Brigitta Bondy; Hans-Jürgen Möller; Michael Riedel
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2008-03-17       Impact factor: 5.270

7.  A novel mechanism and treatment target for presynaptic abnormalities in specific striatal regions in schizophrenia.

Authors:  Vilte E Barakauskas; Clare L Beasley; Alasdair M Barr; Athena R Ypsilanti; Hong-Ying Li; Allen E Thornton; Hubert Wong; Gorazd Rosokilja; J John Mann; Branislav Mancevski; Zlatko Jakovski; Natasha Davceva; Boro Ilievski; Andrew J Dwork; Peter Falkai; William G Honer
Journal:  Neuropsychopharmacology       Date:  2010-01-13       Impact factor: 7.853

8.  Molecular evidence for decreased synaptic efficacy in the postmortem olfactory bulb of individuals with schizophrenia.

Authors:  Chijioke N Egbujo; Duncan Sinclair; Karin E Borgmann-Winter; Steven E Arnold; Bruce I Turetsky; Chang-Gyu Hahn
Journal:  Schizophr Res       Date:  2015-08-07       Impact factor: 4.939

Review 9.  Dysregulations of Synaptic Vesicle Trafficking in Schizophrenia.

Authors:  Chijioke N Egbujo; Duncan Sinclair; Chang-Gyu Hahn
Journal:  Curr Psychiatry Rep       Date:  2016-08       Impact factor: 5.285

10.  Glutamatergic deficits and parvalbumin-containing inhibitory neurons in the prefrontal cortex in schizophrenia.

Authors:  B K Y Bitanihirwe; M P Lim; J F Kelley; T Kaneko; T U W Woo
Journal:  BMC Psychiatry       Date:  2009-11-16       Impact factor: 3.630

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.